Agenus
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The last earnings update was 98 days ago. More info.
Add to Portfolio Compare Print
- Agenus has significant price volatility in the past 3 months.
AGEN Share Price and Events
7 Day Returns
1 Year Returns
AGEN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Agenus (AGEN) | 5.2% | 13.9% | 64.8% | -6% | 14.6% | 7.1% |
| US Biotechs | -0.8% | 0.3% | 5.7% | -1.8% | 14.9% | 7.1% |
| US Market | 0.5% | 6.3% | 1.9% | 2% | 45.1% | 40.5% |
1 Year Return vs Industry and Market
- AGEN underperformed the Biotechs industry which returned -1.8% over the past year.
- AGEN underperformed the Market in United States of America which returned 2% over the past year.
AGEN Value
Is Agenus undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Agenus
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Agenus.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 2 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 13.3% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 7.3% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.43 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.425 (1 + (1- 21%) (2.9%)) |
1.458 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.46 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.458 * 7.27%) |
13.33% |
Discounted Cash Flow Calculation for NasdaqCM:AGEN using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Agenus is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
| Levered FCF (USD, Millions) | -152.30 | -128.40 | -94.20 | -25.40 | 80.70 |
| Source | Analyst x1 | Analyst x1 | Analyst x1 | Analyst x1 | Analyst x1 |
|
Present Value Discounted (@ 13.33%) |
-134.39 | -99.97 | -64.72 | -15.40 | 43.17 |
| Present value of next 5 years cash flows | $-271.31 |
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2023
× (1 + g) ÷ (Discount Rate – g)
= $80.70 × (1 + 2.73%) ÷ (13.33% – 2.73%) |
$782.20 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)5
= $782.20 ÷ (1 + 13.33%)5 |
$418.43 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 5 years cash flows +
Terminal Value
= $-271.31 + $418.43 |
$147.12 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $147.12 / 131.09 |
$1.12 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $1.12 |
| Current discount | Discount to share price of
$3.61
= -1 x ($3.61 - $1.12) / $1.12 |
-221.7% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Agenus is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Agenus's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Agenus's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-09-30) in USD | $-1.39 |
| NasdaqCM:AGEN Share Price ** | NasdaqCM (2019-02-13) in USD | $3.61 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 32 Publicly-Listed Biotechs Companies | 20.45x |
| United States of America Market PE Ratio | Median Figure of 3,046 Publicly-Listed Companies | 16.95x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Agenus.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqCM:AGEN Share Price ÷ EPS (both in USD) = 3.61 ÷ -1.39 |
-2.6x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Agenus is loss making, we can't compare its value to the US Biotechs industry average.
- Agenus is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Agenus's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -2.6x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts |
14.1%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 25 Publicly-Listed Biotechs Companies | 1.91x |
| United States of America Market PEG Ratio | Median Figure of 2,117 Publicly-Listed Companies | 1.36x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Agenus, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Agenus's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-09-30) in USD | $-1.10 |
| NasdaqCM:AGEN Share Price * | NasdaqCM (2019-02-13) in USD | $3.61 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 404 Publicly-Listed Biotechs Companies | 3.03x |
| United States of America Market PB Ratio | Median Figure of 5,122 Publicly-Listed Companies | 1.81x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqCM:AGEN Share Price ÷ Book Value per Share (both in USD) = 3.61 ÷ -1.10 |
-3.28x |
* Primary Listing of Agenus.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Agenus has negative assets, we can't compare the value of its assets to the US Biotechs industry average.
Value checks
We assess Agenus's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Agenus has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
AGEN Future Performance
How is Agenus expected to perform in the next 1 to 3 years based on estimates from 2 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Agenus's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
- Unable to compare Agenus's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
- Agenus's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqCM:AGEN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts | 14.1% |
| NasdaqCM:AGEN Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts | 44.7% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 19.8% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 14.7% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.4% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.1% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 221 | -42 | 2 | |
| 2022-12-31 | 144 | -101 | 2 | |
| 2021-12-31 | 65 | -146 | 2 | |
| 2020-12-31 | 33 | -161 | 2 | |
| 2019-12-31 | 10 | -163 | 2 | |
| 2018-12-31 | 37 | -145 | 2 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-09-30 | 39 | -121 | -147 |
| 2018-06-30 | 29 | -123 | -151 |
| 2018-03-31 | 18 | -120 | -158 |
| 2017-12-31 | 43 | -94 | -121 |
| 2017-09-30 | 40 | -84 | -112 |
| 2017-06-30 | 41 | -82 | -116 |
| 2017-03-31 | 44 | -73 | -113 |
| 2016-12-31 | 23 | -80 | -127 |
| 2016-09-30 | 25 | -83 | -117 |
| 2016-06-30 | 27 | -78 | -89 |
| 2016-03-31 | 27 | -72 | -101 |
| 2015-12-31 | 25 | -47 | -88 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
All data from Agenus Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | -0.34 | 0.35 | -1.02 | 2.00 |
| 2022-12-31 | -0.85 | -0.56 | -1.14 | 2.00 |
| 2021-12-31 | -1.24 | -1.16 | -1.32 | 2.00 |
| 2020-12-31 | -1.38 | -1.34 | -1.41 | 2.00 |
| 2019-12-31 | -1.44 | -1.35 | -1.52 | 2.00 |
| 2018-12-31 | -1.35 | -1.34 | -1.35 | 2.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-09-30 | -1.39 |
| 2018-06-30 | -1.48 |
| 2018-03-31 | -1.57 |
| 2017-12-31 | -1.23 |
| 2017-09-30 | -1.18 |
| 2017-06-30 | -1.26 |
| 2017-03-31 | -1.27 |
| 2016-12-31 | -1.46 |
| 2016-09-30 | -1.35 |
| 2016-06-30 | -1.04 |
| 2016-03-31 | -1.22 |
| 2015-12-31 | -1.13 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Agenus's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Agenus has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
AGEN Past Performance
How has Agenus performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Agenus does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Agenus's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Agenus's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Agenus Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-09-30 | 38.69 | -147.18 | 37.40 | |
| 2018-06-30 | 29.24 | -150.89 | 36.25 | |
| 2018-03-31 | 17.56 | -157.94 | 34.90 | |
| 2017-12-31 | 42.88 | -120.90 | 33.74 | |
| 2017-09-30 | 40.10 | -111.99 | 32.63 | |
| 2017-06-30 | 41.19 | -115.92 | 32.68 | |
| 2017-03-31 | 43.57 | -112.52 | 31.66 | |
| 2016-12-31 | 22.57 | -127.20 | 33.13 | |
| 2016-09-30 | 24.64 | -116.68 | 32.92 | |
| 2016-06-30 | 27.04 | -89.03 | 31.22 | |
| 2016-03-31 | 26.82 | -101.12 | 32.11 | |
| 2015-12-31 | 24.82 | -88.08 | 28.37 | |
| 2015-09-30 | 18.80 | -98.46 | 24.95 | |
| 2015-06-30 | 13.51 | -93.44 | 23.46 | |
| 2015-03-31 | 10.21 | -61.07 | 21.57 | |
| 2014-12-31 | 6.98 | -42.69 | 21.25 | |
| 2014-09-30 | 5.75 | -22.49 | 19.58 | |
| 2014-06-30 | 4.92 | -21.70 | 18.24 | |
| 2014-03-31 | 2.66 | -24.80 | 16.76 | |
| 2013-12-31 | 3.05 | -33.23 | 14.48 | |
| 2013-09-30 | 3.74 | -33.04 | 13.76 | |
| 2013-06-30 | 3.88 | -31.60 | 12.77 | |
| 2013-03-31 | 3.70 | -27.53 | 11.48 | |
| 2012-12-31 | 15.96 | -12.12 | 11.47 | |
| 2012-09-30 | 15.51 | -12.70 | 11.53 | |
| 2012-06-30 | 15.30 | -12.50 | 11.51 | -5.64 |
| 2012-03-31 | 15.46 | -11.34 | 10.82 | -2.82 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Agenus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- It is difficult to establish if Agenus has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Agenus improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Agenus's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Agenus has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
AGEN Health
How is Agenus's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Agenus's finances.
The net worth of a company is the difference between its assets and liabilities.
- Agenus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Agenus's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Agenus has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Agenus Company Filings, last reported 4 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-09-30 | -131.39 | 13.74 | 46.17 |
| 2018-06-30 | -113.09 | 13.74 | 43.16 |
| 2018-03-31 | -113.23 | 13.47 | 52.35 |
| 2017-12-31 | -75.82 | 163.65 | 60.19 |
| 2017-09-30 | -51.59 | 143.94 | 70.05 |
| 2017-06-30 | -17.48 | 139.14 | 96.77 |
| 2017-03-31 | 8.90 | 134.83 | 123.82 |
| 2016-12-31 | -39.13 | 130.69 | 76.44 |
| 2016-09-30 | -21.04 | 126.41 | 95.40 |
| 2016-06-30 | 16.88 | 122.27 | 123.29 |
| 2016-03-31 | 44.45 | 118.31 | 148.23 |
| 2015-12-31 | 70.73 | 114.47 | 171.67 |
| 2015-09-30 | 76.98 | 110.70 | 199.13 |
| 2015-06-30 | 87.19 | 11.43 | 139.64 |
| 2015-03-31 | 46.26 | 11.50 | 79.30 |
| 2014-12-31 | 23.02 | 6.03 | 40.22 |
| 2014-09-30 | 48.87 | 6.72 | 52.91 |
| 2014-06-30 | 57.63 | 7.43 | 62.82 |
| 2014-03-31 | 63.29 | 9.36 | 73.49 |
| 2013-12-31 | -4.48 | 8.87 | 27.35 |
| 2013-09-30 | -2.88 | 9.33 | 30.20 |
| 2013-06-30 | -17.26 | 9.23 | 13.44 |
| 2013-03-31 | -22.68 | 36.35 | 17.21 |
| 2012-12-31 | -17.60 | 35.92 | 21.47 |
| 2012-09-30 | -13.16 | 35.51 | 24.76 |
| 2012-06-30 | -11.36 | 35.20 | 25.46 |
| 2012-03-31 | -10.63 | 33.30 | 24.59 |
- Agenus has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- Irrelevant to check if Agenus's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Agenus has less than a year of cash runway based on current free cash flow.
- Agenus has less than a year of cash runway if free cash flow continues to grow at historical rates of 26.7% each year.
Financial health checks
We assess Agenus's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Agenus has a total score of 1/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
AGEN Dividends
What is Agenus's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Agenus
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Agenus's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Agenus's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 21 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 1997 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.4% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 | ||
| 2018-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Agenus has not reported any payouts.
- Unable to verify if Agenus's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Agenus's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Agenus afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Agenus has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
AGEN Management
CEO
| COMPENSATION | $3,769,681 |
| AGE | 65 |
| TENURE AS CEO | 25.1 years |
CEO Bio
Dr. Garo H. Armen, Ph.D., founded Agenus Inc. in 1994 and has been its Chief Executive Officer since 1994. Dr. Armen serves as an Executive Chairman of Agenus Inc. He has been an Executive Director of Agenus Inc. since 1999. He served as the President of Antigenics since January 2002. Prior to Agenus Inc., he established Armen Partners, a money management firm specializing in biotechnology and pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology business in 1993. Since 1990, Dr. Armen served as the Managing General Partner of Armen Partners, LP, an investment partnership specializing in public and private healthcare and biotechnology investments. He previously served as Senior Vice President of Research for Dean Witter Reynolds, Research Division, focusing on the chemical and pharmaceutical industries and with E.F. Hutton & Company as first Vice President of research. He serves as the Chairman of Protagenic Therapeutics Inc. and Elan Drug Delivery Inc. Dr. Armen served as Chairman of Elan Corporation, plc from July 2002 to January 2005. He has been a Director of Philips Solid-State Lighting Solutions, Inc. (formerly, Color Kinetics Inc.) since 1998. He serves as a Director of ScrollMotion, Inc. He served as a Non Executive Director of Elan Corporation, plc from February 1994 to May 2006. He has served as an Associate Professor at the Merchant Marine Academy and as a Research Associate at the Brookhaven National Laboratory. In 2002, he founded the Children of Armenia Fund and serves as its Chairman. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts and received the Sabin Humanitarian Award from the Sabin Vaccine Institute in 2006 for his achievements in biotechnology and progressing medical research. He was also the Ernst & Young 2002 New York City Biotechnology Entrepreneur of the Year and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr. Armen received his Ph.D. in Physical Organic Chemistry from the City University of New York in 1979.
CEO Compensation
- Garo's compensation has increased whilst company is loss making.
- Garo's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Agenus management team in years:
- The average tenure for the Agenus management team is less than 2 years, this suggests a new team.
Management Team
Garo Armen
Founder
$4M
65
25.1 yrs
Christine Klaskin
Principal Accounting Officer & VP of Finance
$497K
52
12.3 yrs
Alex Duncan
CTO & Head of Research
$858K
56
3.1 yrs
Bob Stein
Senior R&D Advisor
$1M
67
1.8 yrs
Chris Cortis
Chief Strategy Officer & Head of Finance
50
0.7 yrs
Jennifer Buell
Chief Operating Officer
0.3 yrs
Evan Kearns
VP, General Counsel & Secretary
0.6 yrs
Ozer Baysal
Chief Commercial Officer & Head of HR
$462K
62
1.6 yrs
John Castle
Head of Translational Medicine & Bioinformatics
1.1 yrs
Julie DeSander
Vice President of Business Development & Alliance Management
1.1 yrs
Board of Directors Tenure
Average tenure and age of the Agenus board of directors in years:
- The average tenure for the Agenus board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors
Garo Armen
Founder
$4M
65
Wadih Jordan
Independent Director
$212K
83
15.9 yrs
Brian Corvese
Independent Director
$317K
60
11.9 yrs
Tim Wright
Lead Director
$306K
60
10.1 yrs
Ulf Wiinberg
Director
$242K
60
2.8 yrs
Allison Jeynes-Ellis
Director
0.3 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Agenus's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Agenus has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
AGEN News
Simply Wall St News
Agenus Inc (NASDAQ:AGEN): Are Analysts Right About The Drop In Earnings?
Based on Agenus Inc's (NASDAQ:AGEN) earnings update in March 2018,. … with profits predicted to drop by -10.22% next year … compared to its 5-year track record of the average earnings growth rate of -33.80%, this is still an improvement.
Simply Wall St - – Full articleDoes Agenus Inc's (NASDAQ:AGEN) 12.7% EPS Growth Reflect The Long-Term Trend?
Today I will assess AGEN's recent performance announced on 30 September 2017 and compare these figures to its historical trend and industry movements. … See our latest analysis for Agenus How Did AGEN's Recent Performance Stack Up Against Its Past? … I look at the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data.
Simply Wall St - – Full articleDoes Agenus Inc's (AGEN) CEO Pay Compared Well With Peers?
NasdaqCM:AGEN Past Future Earnings Nov 18th 17 Is AGEN's CEO overpaid relative to the market? … Typically I'd use market cap and profit as factors determining performance, however, AGEN's negative earnings lower the effectiveness of this method. … Although remuneration can be a useful gauge of whether Armen's incentives are well-aligned with AGEN's shareholders, it is certainly not sufficient to base your investment decision solely on this factor.
Simply Wall St - – Full articleAGEN Company Info
Map
Description
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies; and partnership with Phyton Biotech. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Details
| Name: | Agenus Inc. |
| AGEN | |
| Exchange: | NasdaqCM |
| Founded: | 1994 |
| $473,249,614 | |
| 131,094,076 | |
| Website: | http://agenusbio.com |
| Address: |
Agenus Inc. 3 Forbes Road, Lexington, Massachusetts, 02421, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqCM | AGEN | Common Stock | Nasdaq Capital Market | US | USD | 04. Feb 2000 | |
| DB | AJ81 | Common Stock | Deutsche Boerse AG | DE | EUR | 04. Feb 2000 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/02/13 23:35 |
| End of day share price update: | 2019/02/13 00:00 |
| Last estimates confirmation: | 2019/01/29 |
| Last earnings filing: | 2018/11/07 |
| Last earnings reported: | 2018/09/30 |
| Last annual earnings reported: | 2017/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
